SWM
AMRX icon

Spire Wealth Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Spire Wealth Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,535
Closed -$19.1K – 2232
2026
Q1 		$19.1K Sell
1,535
-1,023
-40% -$13.7K ﹤0.01% 1439
2025
Q4 		$32.2K Buy
2,558
+1,023
+67% +$11.7K ﹤0.01% 1318
2025
Q3 		$15.4K Hold
1,535
– – ﹤0.01% 1609
2025
Q2 		$12.4K Hold
1,535
– – ﹤0.01% 1649
2025
Q1 		$12.9K Hold
1,535
– – ﹤0.01% 1760
2024
Q4 		$12.2K Hold
1,535
– – ﹤0.01% 1791
2024
Q3 		$12.8K Hold
1,535
– – ﹤0.01% 1573
2024
Q2 		$9.74K Hold
1,535
– – ﹤0.01% 1640
2024
Q1 		$9.3K Buy
+1,535
New +$8.66K ﹤0.01% 1735
2021
Q2 		– Sell
-2,000
Closed -$14K – 2576
2021
Q1 		$14K Buy
+2,000
New +$11.1K ﹤0.01% 2286

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Spire Wealth Management's AMRX Position: Q2 2026 in Review

Spire Wealth Management sold out of Amneal Pharmaceuticals (AMRX) in Q2 2026, closing a stake of 1,535 shares — an estimated $19.1K sold.

Spire Wealth Management first reported a position in AMRX in Q1 2021 and held it in 10 quarters. The position peaked at $32.2K in Q4 2025. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Spire Wealth Management reported no remaining Amneal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Spire Wealth Management sold 1,535 Amneal Pharmaceuticals shares in Q2 2026, an estimated $19.1K.
  • Spire Wealth Management first reported a position in Amneal Pharmaceuticals in Q1 2021 and held it in 10 quarters.
  • Spire Wealth Management's Amneal Pharmaceuticals position peaked at $32.2K in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Spire Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.